Pharmala Biotech Holdings Inc.
MDMA
CNSX
| 02/28/2025 | 11/30/2024 | 08/31/2024 | 05/31/2024 | 02/29/2024 | |
|---|---|---|---|---|---|
| Net Income | -241.88% | -1,404.49% | -171.64% | -21.47% | -209.14% |
| Total Depreciation and Amortization | -22.22% | -15.52% | 112.32% | -96.91% | 19.39% |
| Total Amortization of Deferred Charges | -- | -- | -65.54% | -- | -- |
| Total Other Non-Cash Items | 1,368.65% | 94.88% | 778.21% | 8,075.76% | -296.88% |
| Change in Net Operating Assets | -49.95% | 70.28% | -283.23% | -2,660.71% | 176.18% |
| Cash from Operations | -122.82% | -1,754.29% | 87.71% | 28.52% | -1,654.90% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -1,434.34% | 57.00% | 83.18% | 34.71% | -70.69% |
| Cash from Investing | -1,434.34% | 57.00% | 83.18% | 34.71% | -70.69% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -39.29% | -- | 402.66% | -100.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -39.77% | -- | 382.57% | -100.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 134.39% | -886.76% | 75.29% | 292.40% | -15,188.89% |